Increased prevalence of infectious diseases and other adverse outcomes in human T lymphotropic virus types I- and II-infected blood donors

被引:61
作者
Murphy, EL
Glynn, SA
Fridey, J
Sacher, RA
Smith, JW
Wright, DJ
Newman, B
Gibble, JW
Ameti, DI
Nass, CC
Schreiber, GB
Nemo, GJ
机构
[1] UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143
[2] UNIV CALIF SAN FRANCISCO,DEPT EPIDEMIOL BIOSTAT,SAN FRANCISCO,CA 94143
[3] BLOOD BANK SAN BERNARDINO & RIVERSIDE COUNTIES,SAN BERNARDINO,CA
[4] WESTAT CORP,ROCKVILLE,MD
[5] NHLBI,NIH,BETHESDA,MD 20892
[6] GEORGETOWN UNIV HOSP,WASHINGTON,DC 20007
[7] OKLAHOMA BLOOD INST,OKLAHOMA CITY,OK
[8] AMER RED CROSS,BLOOD SERV,DETROIT,MI
关键词
D O I
10.1086/514143
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Disease associations of human T lymphotropic virus types I and II (HTLV-I and -II) infection were studied in 154 HIV-I-infected, 387 HTLV-II-infected, and 799 uninfected blood donors. Adjusted odds ratios (ORs) and 99% confidence intervals (CIs) were derived from logistic regression models controlling for demographics and relevant confounders. All subjects were human immunodeficiency virus type l-seronegative, HTLV-II was significantly associated with a history of pneumonia (OR, 26; 99% CI, 1.2-5.3), minor fungal infection (OR, 2.9; 99% CI, 1.2-7.1), and bladder or kidney infection (OR, 1.6; 99% CI, 1.0-2.5) within the past 5 years and with a lifetime history of tuberculosis (OR, 3.9; 99% CI, 1.3-11.6) and arthritis (OR, 1.8; 99% CI, 1.2-2.9). Lymphadenopathy (greater than or equal to 1 cm) was associated with both HTLV-I (OR, 6.6; 99% CI, 2.2-19.2) and HTLV-II (OR, 2.8; 99% CI, 1.1-7.1) infection, although no case of adult T cell leukemia/lymphoma was diagnosed. Urinary urgency and gait disturbance were associated with both viruses. This new finding of increased prevalence of a variety of infections in HTLV-II-positive donors suggests immunologic impairment.
引用
收藏
页码:1468 / 1475
页数:8
相关论文
共 45 条
[1]  
BARTHOLOMEW C, 1987, LANCET, V2, P1469
[2]  
BROWN LS, 1991, J NATL MED ASSOC, V83, P677
[3]  
BUSCH MP, 1994, BLOOD, V83, P1143
[4]  
DELAPORTE E, 1989, J ACQ IMMUN DEF SYND, V2, P410
[5]  
GEBRETSADIK T, 1994, AIDS CLIN REV 1993 1
[6]   CHRONIC MYELOPATHY ASSOCIATED WITH HUMAN T-LYMPHOTROPIC VIRUS TYPE-I (HTLV-I) [J].
GESSAIN, A ;
GOUT, O .
ANNALS OF INTERNAL MEDICINE, 1992, 117 (11) :933-946
[7]   NON-HODGKIN LYMPHOMA IN JAMAICA AND ITS RELATION TO ADULT T-CELL LEUKEMIA-LYMPHOMA [J].
GIBBS, WN ;
LOFTERS, WS ;
CAMPBELL, M ;
HANCHARD, B ;
LAGRENADE, L ;
CRANSTON, B ;
HENDRIKS, J ;
JAFFE, ES ;
SAXINGER, C ;
ROBERTGUROFF, M ;
GALLO, RC ;
CLARK, J ;
BLATTNER, WA .
ANNALS OF INTERNAL MEDICINE, 1987, 106 (03) :361-368
[8]   HUMAN T-CELL LEUKEMIA-LYMPHOMA VIRUS, TYPE-II (HTLV-II) - EMERGENCE OF AN IMPORTANT NEWLY RECOGNIZED PATHOGEN [J].
HALL, WW ;
KUBO, T ;
IJICHI, S ;
TAKAHASHI, H ;
ZHU, SW .
SEMINARS IN VIROLOGY, 1994, 5 (02) :165-178
[9]   SPASTIC ATAXIA ASSOCIATED WITH HUMAN T-CELL LYMPHOTROPIC VIRUS TYPE-II INFECTION [J].
HARRINGTON, WJ ;
SHEREMATA, W ;
HJELLE, B ;
DUBE, DK ;
BRADSHAW, P ;
FOUNG, SKH ;
SNODGRASS, S ;
TOEDTER, G ;
CABRAL, L ;
POIESZ, B .
ANNALS OF NEUROLOGY, 1993, 33 (04) :411-414
[10]   An International Collaborative Study of the effects of coinfection with human T-Lymphotropic virus type II on human immunodeficiency virus type 1 disease progression in injection drug users [J].
Hershow, RC ;
Galai, N ;
Fukuda, K ;
Graber, J ;
Vlahov, D ;
Rezza, G ;
Klein, RS ;
Jarlais, DCD ;
Vitek, C ;
Khabbaz, R ;
Freels, S ;
Zuckerman, R ;
Pezzotti, P ;
Kaplan, JE .
JOURNAL OF INFECTIOUS DISEASES, 1996, 174 (02) :309-317